Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open-Label Study of the Safety, Tolerability and Efficacy of the Selegiline Transdermal System in Elderly Subjects With Major Depression

NCT00285766 is registered in ClinicalTrials.gov with Somerset Pharmaceuticals as lead sponsor.

NCT NCT00285766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00285766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open-Label Study of the Safety, Tolerability and Efficacy of the Selegiline Transdermal System in Elderly Subjects With Major Depression
Lead sponsor
Somerset Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2002
Completion date
July 31, 2005
Enrollment
300
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

major depression